Post-traumatic headache after mild traumatic brain injury in a one-year follow up study - risk factors and return to work [0.03%]
轻度脑外伤后头痛的预后研究——危险因素和重返工作岗位后的状况
Yvonn Kraemer,Kaisa Mäki,Ivan Marinkovic et al.
Yvonn Kraemer et al.
Background: Post-traumatic headache (PTH) is a common symptom following mild traumatic brain injury (mTBI). Patients at risk to develop acute PTH (aPTH) and further persistent PTH (pPTH) need to be recognized. ...
Lasmiditan and 5-Hydroxytryptamine in the rat trigeminal system; expression, release and interactions with 5-HT1 receptors [0.03%]
激光滴達ん和5-羥色胺在大鼠三叉神经系统的表达、释放及其与5-HT1受体的相互作用
Jacob C A Edvinsson,Aida Maddahi,Isabella M Christiansen et al.
Jacob C A Edvinsson et al.
Background: 5-Hydroxytryptamine (5-HT) receptors 1B, 1D and 1F have key roles in migraine pharmacotherapy. Selective agonists targeting these receptors, such as triptans and ditans, are effective in aborting acute migrain...
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model [0.03%]
鞘氨醇-1-磷酸受体1参与硝酸甘油反复诱导的慢性偏头痛模型中枢敏化作用
Qi Pan,Yunfeng Wang,Ruimin Tian et al.
Qi Pan et al.
Background: Central sensitization is an important pathophysiological mechanism of chronic migraine (CM), and microglia activation in trigeminocervical complex (TCC) contributes to the development of central sensitization....
Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients [0.03%]
法布诺单抗治疗日本和韩国患者群癫痫发作性和慢性 migrainefromFremanezumab 在日本和韩国偏头痛患者中的疗效起效早：来自 2 项 2b/3 期试验的事后分析
Takao Takeshima,Masami Nakai,Yoshiyuki Shibasaki et al.
Takao Takeshima et al.
Background: Early onset of action has become recognized as an important efficacy feature of preventive migraine treatment, which can help overcome adherence issues commonly associated with older medications. Preventive tr...
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials [0.03%]
恩太昔单抗治疗≥75%患者报告结果、与健康相关的生活质量和急性期用药：PROMISE试验亚组汇总分析
Richard B Lipton,Larry Charleston th,Cristina Tassorelli et al.
Richard B Lipton et al.
Background: PROMISE-1 and PROMISE-2 evaluated the preventive efficacy, tolerability, and safety of eptinezumab, a calcitonin gene-related peptide-targeted monoclonal antibody, in adults with episodic (EM) and chronic migr...
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study [0.03%]
在偏头痛发作时开始使用Eptinezumab治疗与患者报告的结果测量指标显著改善相关：来自随机对照RELIEF研究的次要结果
Peter McAllister,Paul K Winner,Jessica Ailani et al.
Peter McAllister et al.
Background: Demonstrating therapeutic value from the patient perspective is important in patient-centered migraine management. The objective of this study was to investigate the impact of eptinezumab, a preventive migrain...
Randomized Controlled Trial
The journal of headache and pain. 2022 Feb 7;23(1):22. DOI:10.1186/s10194-021-01376-7 2022
Dynamic brainstem and somatosensory cortical excitability during migraine cycles [0.03%]
偏头痛发作周期中的脑干和躯体感觉皮层兴奋性动态变化
Fu-Jung Hsiao,Wei-Ta Chen,Li-Ling Hope Pan et al.
Fu-Jung Hsiao et al.
Background: Migraine has complex pathophysiological characteristics and episodic attacks. To decipher the cyclic neurophysiological features of migraine attacks, in this study, we compared neuronal excitability in the bra...
The applicability research of the diagnostic criteria for 6.7.2 angiography headache in the international classification of headache disorders-3rd edition [0.03%]
国际头痛疾病分类第三版中6.7.2造影剂性头痛诊断标准适用性研究
Chenglong Lu,Leyi Zhang,Jun Wang et al.
Chenglong Lu et al.
Background: Angiography headache (AH) is common but not negligible, and the criteria for AH have been based on only a few studies. The purpose of this study was to investigate the incidence, risk factors and possible mech...
The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials [0.03%]
抗偏头痛药物atogepant预防性治疗 migraine的疗效和安全性：来自随机对照试验的证据
Xinyu Tao,Zeya Yan,Jiahao Meng et al.
Xinyu Tao et al.
Background: Migraine is a common neurovascular disorder that has a severe impact on the individual daily life. Atogepant (AGN-241689) is an orally ingested, small-molecule drugs belonging to calcitonin gene-related peptid...
Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms [0.03%]
颅自主神经症状：偏头痛及其他两种潜在新病症中的流行病学、表型及侧别分布研究
Nazia Karsan,Karthik Nagaraj,Peter J Goadsby
Nazia Karsan
Background: Whilst cranial autonomic symptoms (CAS) are typically associated with trigeminal autonomic cephalalgias (TAC's), they have also been reported in migraine. Identification and understanding of these symptoms in ...